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Approximately 730,000 strokes occur annually in
the United States.1 The survivors of stroke account
for $30 billion annually in health care costs and lost
productivity. Fortunately, carotid endarterectomy
(CEA) has emerged as an effective intervention that
reduces the incidence of future stroke in patients
with symptomatic carotid artery stenosis. The North
American Symptomatic Carotid Endarterectomy
Trial (NASCET) was the first study to unequivocally
establish the role of endarterectomy in the treatment
of carotid artery stenosis. In this trial, symptomatic
patients with stenosis of 30% to 99% that involved the
ipsilateral carotid artery were prospectively random-
ized to either CEA or the best medical treatment.
The first publication from this trial in 1991 included
data from 659 patients with 70% to 99% carotid
stenosis.2 Although NASCET was initially designed
as a 5-year trial, a markedly significant benefit for
CEA was found in this cohort of patients after only
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18 months. The 30-day mortality and stroke mor-
bidity rate was 5.8% in patients randomized to CEA.
The cumulative 2-year risk of ipsilateral stroke was
26% in patients who underwent medical treatment
and 9% in patients who underwent CEA, represent-
ing an absolute risk reduction of 17% and a relative
risk reduction of 65%.
After this initial report from NASCET, the
recruitment of symptomatic patients with 30% to
69% stenosis markedly diminished. However, by
1998, a sufficient accrual of patients allowed the
data from this cohort to be reported.3 Two sub-
groups were defined: those patients with 30% to 49%
carotid stenosis and those patients with 50% to 69%
stenosis. For the patients with 50% to 69% stenosis,
the risk of ipsilateral stroke at 5 years was 22.2% with
medical treatment versus 15.7% with CEA, yielding
a statistically significant absolute risk reduction of
6.5% and a relative risk reduction of 29%. For the
patients with carotid stenosis less than 50%, the 5-
year risk of ipsilateral stroke was 18.7% with medical
treatment versus 14.9% with surgery, yielding a non-
significant absolute risk reduction of only 3.8%.
Thus, NASCET revealed a beneficial effect for
CEA in symptomatic patients with carotid stenosis
greater than 50%. However, the benefit of surgery in
patients with 50% to 69% carotid stenosis was signifi-
cantly less than that for patients with 70% to 99%
stenosis. It has been calculated that 15 patients with
50% to 69% carotid stenosis need to undergo treat-
ment with endarterectomy to prevent one ipsilateral
stroke at 5 years versus only 8 patients with 70% to
99% stenosis.3 The benefit of CEA in patients with
50% to 69% stenosis was sufficiently small that the
appropriateness and cost-effectiveness of performing
CEA in this cohort has been questioned. To address
these issues, we constructed a decision-analysis model
to calculate the lifetime costs and life expectancies for
a hypothetical cohort of patients with 50% to 69%
carotid stenosis who underwent treatment with either
CEA or medical treatment alone. Our goal was to
define whether the practice of CEA in these patients
is cost-effective within the limits deemed acceptable
by society.
METHODS
The decision analysis model
We developed a decision-analysis model that
reflected the possible clinical outcomes and costs
associated with a hypothetical 66-year-old cohort of
patients with symptomatic 50% to 69% carotid steno-
sis. The patients were designated to undergo either
CEA or the best medical treatment. Treatment with
either strategy was associated with numerous possible
30-day outcomes, including perfect health (ie, no
stroke), minor and major stroke (as defined in
NASCET), or death (Fig 1). After 30 days, the
patients in each cohort then entered a Markov
process in which transitions to other states could
occur annually (Fig 2).4 A multitude of outcomes
was associated with each strategy according to an
assigned set of probabilities on the basis of data
derived from NASCET and other relevant literature.
The costs for the procedures and outcomes were
assigned on the basis of data from our institution and
the relevant literature. A computerized decision-
analysis Markov process model (SMLTREE software,
version 2.9, James P. Hollenberg, Roslyn, NY) was
used to track the outcomes and costs. This model fol-
lowed the hypothetical cohort until all patients died.
The endpoints for the model included: (1) long-term
survival in quality-adjusted life years (QALYs), and
(2) the lifetime treatment costs for each strategy. Our
measure of outcome was the cost-effectiveness ratio,
defined as the additional cost per QALY gained by
CEA. Cost-effective analyses are made on the
premise that two strategies are being compared. If
the strategy being evaluated costs more and is less
effective than the alternative, then this strategy is
clearly not cost-effective and should not be adopted
(Table I). If a strategy costs more but is more effec-
tive than the alternative, then a cost-effectiveness
ratio can be determined. The lower the ratio, the
more cost-effective the intervention. If a strategy
costs less and is more beneficial than the alternative,
then a cost-effectiveness ratio cannot be determined.
Under this circumstance, the strategy is considered
to be cost saving and should clearly be adopted.
In our initial (base-case) analysis, the single
best estimates of probabilities, costs, and quality-
adjustment factors were used. These variables were
systematically varied through a wide plausible
range, and the effect of these variations on the
base-case conclusion was determined. This process
is termed sensitivity analysis. Because most widely
accepted medical interventions have cost-effective-
ness ratios of less than $60,000, we considered
this value to be the threshold for our sensitivity
analyses.5 All the costs were converted to 1997 US
dollars with the medical care component of the
Consumer Price Index for All Urban Consumers.
In accordance with standard principles of econom-
ic analysis, the costs and life expectancies were dis-
counted at 3% per year to reflect the greater value
of current dollars and life years as compared with
that of the future.6
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Assumptions
Probabilities. For the probabilities assigned to
our base-case analysis, we used data from the recent
NASCET publication in which the outcomes of
patients with 50% to 69% carotid stenosis were
addressed.3 The influence of disease in the con-
tralateral carotid artery on outcome was not evaluat-
ed in NASCET. Thus, this factor was not included in
our analysis. The 30-day probabilities of stroke and
death for patients randomized to CEA or medical
treatment were 6.6% (minor stroke, 4.6%; major
stroke, 0.8%; and death, 1.2%) and 2.4% (minor
stroke, 1%; major stroke, 1%; and death, 0.4%),
respectively.
The data from NASCET indicated that the annu-
al rate of ipsilateral stroke after 30 days for sympto-
matic patients with 50% to 69% stenosis who under-
went medical treatment was highest in the first year
after the ischemic event. We estimated that the decre-
mental risk of an ipsilateral stroke (major, minor) was:
first year, 9.3% (2.6%, 6.7%); second year, 4% (1.1%,
2.9%); and 3% (0.9%, 2.1%) for subsequent years (M.
Eliasziw, MD, personal communication, December
1998). Among the patients who underwent surgical
treatment, the annual rate of ipsilateral stroke after 30
days was 3% (0.6%, 2.4%) for the first year and then
was constant at 2% per year (0.4%, 1.6%) for the sub-
sequent years. The benefit of surgery was assumed to
persist for 5 years after endarterectomy. After 5 years,
we assumed that the medical and surgical stroke risks
were equivalent at 3% per year.
It was estimated that 18% of major strokes are
fatal and that patients who survive a major stroke
have an excess mortality rate of 7.7% per year.2,7,8
Age-specific annual mortality rates from other caus-
es were on the basis of standard US life tables.9 An
excess mortality rate of 6.3% per year was assigned to
the cohort of patients with symptomatic 50% to 69%
carotid stenosis to account for the increased risk of
cardiac-related death in this population.10
Costs. The cost (not the charge) of CEA, includ-
ing anesthesia, was estimated at $5100 from the New
York Presbyterian Hospital–Cornell Campus cost
accounting system. This number was derived with the
review of the cost associated with the most recent 50
CEAs performed by the senior author. A professional
fee for the surgeon of $1320 was derived from the
Medicare reimbursement for the Current Procedural
Fig 1. In first portion of decision tree, a hypothetical cohort with symptomatic 50% to 69%
carotid stenosis may undergo either carotid endarterectomy or medical treatment alone.
Possible 30-day outcomes of each strategy include perfect health (no event), minor stroke,
major stroke, or death. Each patient then enters a Markov process state.
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Terminology code for CEA (geographically unadjust-
ed), which resulted in an overall cost for CEA of
$6420.
The direct costs of stroke were estimated from the
literature.11 We used $9300 as the average cost for
hospitalization for patients with minor strokes, plus a
subsequent annual cost of $798 for outpatient care.
We estimated that 30% of the patients who survived a
major stroke would undergo inpatient rehabilitation
followed by outpatient and home health care. The
remainder would reside in nursing homes. With these
assumptions, we derived a cost of $51,150 for the first
year after a major stroke and an annual cost of
$26,880 for subsequent years. For patients in whom
a stroke did not develop, an annual cost of $63 was
assigned to reflect the cost of aspirin therapy.
Quality adjustment. Because the quality of life
associated with some health states may be less desir-
able than those of others, life expectancy is adjusted
for quality of life. The quality-adjustment factor may
range from 0 (death) to 1 (perfect health). We used
a quality-adjustment factor of 0.40 for patients who
survived a major stroke.12 To calculate the QALYs in
a patient who has had a major stroke, only 40% of
that year is credited for each year that the patient
survives. The patients who had a minor stroke were
assigned a disutility of 0.25 years, meaning that 3
months were subtracted from their overall quality-
adjusted life expectancy.
RESULTS
Base-case analysis
For the typical 66-year-old patient with 50% to
69% carotid stenosis in NASCET, CEA provided an
additional 0.13 QALYs (6.75 QALYs for CEA; 6.62
QALYs for medical treatment) at an additional life-
time cost of $580 ($16,269 for CEA; $15,689 for
medical treatment). This yielded a cost-effectiveness
ratio of $4462 ($580/0.13).
Sensitivity analyses
The base-case assumptions were tested in sensi-
tivity analyses with the substitution of a wide range
of values for each variable (Table II). This process
allowed the determination of the variables that had
the greatest impact on the outcome of our analysis.
Perioperative risk of stroke and death. We
assigned a perioperative risk of stroke and death for
CEA of 6.6%. If the risk of stroke or death was
Fig 2. The schematic represents the second portion of
the decision tree (after 30 days). The Markov process
allows transitions between states of health. For example, if
a patient sustained a minor stroke at 30 days, during the
next year, the patient may have no other event, may go on
to have major stroke, or may die. If a patient sustained
major stroke at 30 days, the patient may either die or stay
in the same state. The patient cannot make transition to
the minor stroke state. These transitions can occur over
the lifetime of the patient.
Fig 3. Effect of perioperative risk of stroke or death on
cost-effectiveness of carotid endarterectomy in sympto-
matic patients with 50% to 69% carotid stenosis. Dotted
line indicates $60,000 threshold for accepted medical
interventions.
CER, Cost-effectiveness ratio; QALY, quality-adjusted life
year.
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reduced to 5%, the cost-effectiveness ratio was
reduced from $4462 to $654 (Fig 3). The halving of
the perioperative rates of minor and major stroke
and mortality (overall perioperative event rate, 3.3%)
made CEA cost saving (ie, lower lifetime expendi-
tures and greater life expectancy). Alternatively, if
the perioperative risk of stroke and death exceeded a
value of 11.3%, CEA was no longer cost-effective
(ratio > $60,000 threshold).
Annual ipsilateral stroke rate associated with
medical and surgical treatment. The risk of ipsi-
lateral stroke in the first year, excluding perioperative
events, was 9.3% with medical treatment and 3%
with CEA, representing a numerical reduction in
stroke provided by CEA of 6.3%. If this numerical
reduction was reduced to 1.3% (either with the
reduction of the risk of stroke in patients who
underwent medical treatment or with the increase of
the risk of stroke in patients who underwent surgical
treatment), then CEA no longer was cost-effective
(ratio > $60,000; Fig 4). If the numerical benefit for
surgery in the first year increased from 6.3% to 8%,
then CEA became cost saving.
In the third year through the fifth year, the annu-
al risk of ipsilateral stroke with medical treatment
was 3% and the risk of stroke with surgery was 2%,
resulting in a numerical reduction in stroke of 1%
per year. If this numerical reduction was increased to
2%, then CEA became cost saving. If the numerical
benefit of surgery was reduced to 0% for the third
year through the fifth year, then the cost-effective-
ness ratio for CEA increased from $4462 to
$12,332.
Although surgery clearly had a beneficial effect
in the first 5 years, we assumed in our model that
there was no surgical benefit after 5 years. If the
duration of surgical benefit was not terminated at 5
years but instead was extended to 8 years, then CEA
was cost saving.
Cost of carotid endarterectomy. For our base-
case analysis, we determined a cost of $6420 for
CEA. However, this cost is highly variable among
institutions and surgeons. If the cost of CEA dimin-
ished to $5000, CEA became cost saving. If the cost
of CEA rose to a level exceeding $13,200, then
CEA was no longer cost-effective (ratio > $60,000).
If CEA was performed at a cost of $15,000, the
cost-effectiveness ratio increased to a prohibitive
value of $75,091. 
Age
Our base-case analysis was performed for a 66-
year-old patient, representing the average age of the
patients who participated in NASCET. With the
assumption that the model’s other variables
remained unchanged, the cost-effectiveness of CEA
was further enhanced in patients who were less than
66 years of age because of their increased life
expectancy (Fig 5). For example, CEA was cost sav-
ing for patients less than 60 years of age. The cost-
effectiveness ratio for a 90-year-old patient was high
at $136,740. With the presumption of a $60,000
threshold for cost-effectiveness, CEA was not cost-
effective for patients who were more than 83 years
of age (ratio > $60,000).
Table I. Analysis of cost-effectiveness of a new strategy versus the alternative
Costs Effectiveness Cost-effectiveness Conclusion
Costs more Less effective Not cost-effective Do not adopt strategy
Costs less More effective Determine cost-effectiveness ratio Adopt strategy if ratio is less than $60,000
Costs less More effective Cost-savings Adopt strategy
Table II. Base-case assumptions and ranges tested
in sensitivity analysis
Variable Base-case Range
Rate of stroke and death (30 days)
CEA 6.6% 3% to 11%
Med 2.4%
Rate of stroke (1st year)
CEA 3.0%
Med 9.3%
Numerical reduction 6.3% 1% to 8%
Rate of stroke (3rd to 5th year)
CEA 2.0%
Med 3.0%
Numerical reduction 1.0% 0.0% to 2.0%
Treatment costs
CEA $6420 $5000 to $15,000
Major stroke (annual) $26,880 $0 to $30,000 
Minor stroke (annual) $798 $0 to $5000
Age (years) 66 60 to 90
Quality adjustment 0.4 0.2 to 1.0
factor (major stroke)
CEA, Carotid endarterectomy; med, medical management;
numerical reduction, the numerical difference between carotid
endarterectomy and medical management.
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Other variables. If the utility assigned to major
stroke was reduced from the base-case value of 0.4
to 0.2, the cost-effectiveness ratio was lowered from
$4462 to $3654. If the utility was raised to 1.0, the
cost-effectiveness ratio increased to $49,720. If the
annual cost of major stroke was varied over a range
of $0 to $30,000 (base-case, $26,880), the cost-
effectiveness ratio changed from $38,197 to $751.
The annual cost of minor stroke had an insubstantial
effect on the cost-effectiveness ratio. If its cost was
varied over a range from $0 to $5000 (base-case,
$798), the cost-effectiveness ratio ranged from
$5411 to $1306. If the excess annual mortality rate
assigned to the entire cohort as the result of the
presence of cardiac disease in patients with carotid
disease was halved from 6.3% to 3.15%, the cost-
effectiveness ratio decreased to $1506. The dou-
bling of the excess mortality rate to 12.6% per year
increased the ratio to $18,948. If we decreased the
discount rate from 3% to 0%, then CEA was cost sav-
ing. If we raised the discount rate to 10%, the cost-
effectiveness ratio increased to $29,216.
DISCUSSION
Recent data from NASCET revealed a benefit
for CEA in symptomatic patients with moderate
(50% to 69%) stenosis.3 This benefit was statistical-
ly significant. However, the 5-year numerical reduc-
tion in stroke provided by CEA was small (6.5%).
Consequently, the authors of NASCET were tenta-
tive in recommending operation for this cohort of
patients. They concluded in their recent publication
that “many patients with symptomatic stenosis of
less than 70% will not be considered appropriate
candidates for endarterectomy when the risks and
benefits are carefully weighed.”3 Their concern rais-
es the obvious question of how much benefit must
be derived from CEA before the use of this proce-
dure is regarded as appropriate. Ultimately, patients
must decide whether or not to submit to surgery.
Faced with a small but definite advantage of CEA in
reducing stroke, one patient may opt for surgery
because of a profound fear of future stroke, where-
as another patient may refuse surgery because of the
inconvenience and anxiety associated with an oper-
ative procedure. Alternatively, with rapidly dimin-
ishing economic resources, society (under the aus-
pices of the Health Care Financing Administration),
may opt to make this decision on the basis of a rela-
tionship between medical benefit and the cost of
the procedure.
To assess the cost-effectiveness of CEA in symp-
tomatic patients with 50% to 69% carotid stenosis,
we constructed a Markov decision-analysis model in
which the strategies of CEA and medical manage-
ment were compared. Markov modeling allows the
creation of a relationship between the risk reduction
provided by an intervention and the cost over the
lifetime of a patient. Outcome is measured in cost
per QALY gained (ie, the cost-effectiveness ratio).
Fig 4. Effect of medical stroke risk in first year after onset
of ischemic symptoms (excluding perioperative events) on
cost-effectiveness of carotid endarterectomy in sympto-
matic patients with 50% to 69% carotid stenosis. Dotted
line indicates $60,000 threshold for accepted medical
interventions.
CER, Cost-effectiveness ratio; QALY, quality-adjusted life
year.
Fig 5. Effect of patient age on cost-effectiveness of
carotid endarterectomy in symptomatic patients with 50%
to 69% carotid stenosis. Dotted line indicates $60,000
threshold for accepted medical interventions.
CER, Cost-effectiveness ratio; QALY, quality-adjusted life
year.
This value can then be compared with similar ratios
that have been derived for already established and
accepted medical interventions.
We found that symptomatic patients with 50% to
69% carotid stenosis who underwent treatment with
CEA had a longer life expectancy and a better quality
of life (an additional of 0.13 QALYs) than the patients
who underwent treatment with medical therapy alone,
although the patients who underwent treatment with
CEA also incurred higher lifetime costs (an additional
cost of $580). We derived a cost-effectiveness ratio of
$4462, which is well within the range that is consid-
ered an acceptable and appropriate allocation of soci-
etal resources. Although the precise value that society
is willing to pay for an intervention is elusive, most
common medical interventions have cost-effectiveness
ratios of less than $60,000.5 Examples of cost-effec-
tiveness ratios include: $9500 for coronary artery
bypass grafting for left main disease,13 $19,400 for
surgical repair of 4-cm abdominal aortic aneurysms,14
and $54,400 for hemodialysis for end-stage renal dis-
ease.15 Thus, CEA in symptomatic patients with 50%
to 69% stenosis is clearly cost effective. For compari-
son, we updated our previous cost-effectiveness analy-
sis of symptomatic patients with 70% to 99% carotid
stenosis with current cost and longer term follow-up
data.16 We found that in symptomatic patients with
70% to 99% carotid stenosis, CEA was cost saving with
both lower lifetime expenditures and greater life
expectancy as compared with medical management
(Table I). Because CEA for these patients is the pre-
ferred option from the standpoint of both cost and
benefit, no cost-effectiveness ratio can be calculated.
Thus, the cost-effectiveness of CEA in patients with
symptomatic 50% to 69% stenosis is less than that for
patients with high-grade stenoses. However, the cost-
effective ratio for CEA in patients with moderate
stenoses is still less than that of a multitude of com-
monly performed interventions that are currently con-
sidered acceptable by society.
There have been two other prospective random-
ized trials that have evaluated patients with 50% to
69% symptomatic carotid stenosis. In the Veteran
Affairs study, 189 symptomatic patients with greater
than 50% ipsilateral carotid stenosis were random-
ized to either CEA or medical therapy.17 The
authors of this study found no statistically significant
difference in the rate of stroke or transient ischemic
attack between the two treatment strategies when
the 58 patients with 50% to 69% stenosis were com-
pared (7.1% for CEA vs 6.7% for medical manage-
ment). In the European Carotid Surgery Trial, 401
patients with carotid stenosis that ranged from 70%
to 79% (equivalent to 50% to 65% stenosis in
NASCET) were randomized to either CEA or med-
ical management.18 The risk of a major stroke or
death at 3 years was statistically equivalent for
surgery and medical therapy (38.5% for CEA vs
40.6% for medical treatment). However, the 30-day
risk of major stroke or death with surgery was sur-
prisingly high at 9.1%. To date, NASCET provides
the largest number of patients with 50% to 69%
carotid stenosis prospectively randomized to CEA or
medical management (858 patients), with the
longest period of follow-up (5 years). Moreover, the
perioperative risk of stroke and death (6.6%) is more
consistent with recent publications.19,20 For these
reasons, and despite the findings of these previous
studies, we used only data from NASCET in the
construction of our model.
We sought to determine the conditions that
allowed CEA in symptomatic patients with moderate
carotid stenosis to remain cost-effective. The follow-
ing variables were found to influence the cost-effec-
tiveness of this procedure: the perioperative risk, the
medical and surgical annual ipsilateral stroke rates
after 30 days, the cost of CEA, and patient age.
The perioperative stroke and death rate in the
patients with 50% to 69% carotid stenosis was 6.6% in
NASCET. This is a higher value than the 5.8% that
was reported in the first NASCET cohort of patients
with 70% to 99% stenosis.2 This is a surprising finding
because, in the original NASCET study, the Veteran
Affairs trial, and the European Carotid Surgery Trial,
there did not appear to be a relationship between
perioperative risk of stroke and death and the degree
of carotid stenosis. If we used 5.8% as the periopera-
tive stroke or death rate for our analysis, the cost-
effectiveness ratio diminished from $4462 to $2552.
There are several multicenter studies in which periop-
erative stroke and death rates in the 2% to 3% range
have been reported.21,22 The Cleveland Vascular
Society observed a stroke and death rate of 2.9%
among 7480 symptomatic patients who underwent
CEA.21 In a report from the Kentucky Vascular
Surgical Society, the incidence of stroke or death
among 568 symptomatic patients was 2.3%.22 With a
stroke and death rate lower than 3%, CEA is cost sav-
ing. Alternatively, if the perioperative stroke or death
rate is raised to a value greater than 11.3%, the cost-
effectiveness ratio for CEA in patients with moderate
stenosis exceeded $60,000. There is evidence that
perioperative stroke and mortality risk is increased
with surgeons who perform CEA infrequently.19,21,23
Kucey et al23 noted that surgeons who performed
fewer than 6, 6 to 12, and greater than 12 CEAs
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stroke rate is much smaller during the first 2 years
after the recognition of disease. Consequently, in
asymptomatic patients, CEA is cost-effective only if
patients survive for several years.
The age of the patient was an important factor in
our analysis. In our base-case analysis, we assumed
that our hypothetical cohort consisted of 66-year-
old patients (the average age in NASCET). We
found that CEA was not cost-effective in sympto-
matic patients with 50% to 69% stenosis who were
older than 83 years of age (ie, cost-effectiveness ratio
exceeds $60,000). This is not surprising because
younger patients have more opportunity to accrue
the benefit provided by surgery. The sensitivity
analysis for age was performed with the assumption
that only age would be varied and that all other vari-
ables would remain constant. Many authors have
noted that older patients have a higher perioperative
risk.26,27 In a study of 108,275 Medicare beneficia-
ries, the patients who were older than 85 years had
double the perioperative mortality rate as compared
with the patients between the ages of 65 and 74
years.26 If we simultaneously vary both age and
operative mortality rate in our sensitivity analysis,
the age at which CEA is no longer cost-effective fur-
ther diminishes.
The hospitalization cost of CEA is another
important determinant of the cost-effectiveness of
CEA in patients with moderate carotid stenosis. In
our base-case analysis, we used $6420 as the cost for
CEA. In our institution, we have incorporated sev-
eral cost-saving measures to reduce the cost of CEA:
elimination of carotid arteriography, same-day
admisssion, selective intensive care unit admission,
and discharge on the day after surgery. These cost-
efficient measures have been implemented with low
morbidity and mortality. Several studies have now
substantiated that CEA can be safely performed with
this strategy with a resultant diminution in expens-
es.28-30 We found that if the cost of CEA is raised to
$13,200, then the cost-effectiveness ratio is
increased to a value greater than $60,000. Thus, it is
important that CEA be performed efficiently so that
it can remain a cost-effective alternative to medical
and other invasive interventions for carotid artery
disease.
Stroke imposes a major economic burden on our
healthcare system. With the aging of the population,
both the human and economic burden of stroke will
substantially increase, making interventions aimed at
stroke prevention tremendously important. In this
analysis, we have found that CEA for moderate
symptomatic carotid stenosis is an economically effi-
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annually had perioperative stroke and mortality rates
of 18.4%, 8%, and 5.4%, respectively. For CEA to
remain cost-effective in this patient cohort, a reason-
ably low perioperative rate of stroke and death must
be assured.
For the patients who underwent medical treat-
ment, the risk of stroke was greatest in the first year
after the procedure and then declined (9.3% for the
first year, 4% for the second year, and 3% for each
year thereafter; M. Eliasziw, PhD, personal commu-
nication, December 1998). For surgical treatment,
the stroke rate was 3% during the first year and then
2% for each of the subsequent years. The primary
benefit of CEA was achieved in the first year after the
onset of ischemic symptoms during which the dif-
ference in stroke rate between medical and surgical
treatment was: 9.3% – 3% = 6.3%. If the medical
stroke risk for the first year was lowered from 9.3%
to 4.3%, which would result in a 1.3% difference
between the medical and surgical risk of stroke, then
CEA was no longer cost-effective (ratio, $61,195).
The variations in the late stroke rate (after 2 years)
for both the medical and the surgical groups had
negligible effects on the cost-effectiveness of this
procedure. The annual risks of ipsilateral stroke after
2 years for patients who underwent medical and sur-
gical treatment were 3% and 2%, respectively. If we
assumed that the risk of stroke after 2 years was
equivalent at 2% in the medically and surgically treat-
ed groups, then CEA was still cost-effective (the
cost-effectiveness ratio increased insignificantly from
$4462 to $12,332). Thus, the cost-effectiveness of
CEA in these patients is largely dependent on the
reduction in stroke conferred by CEA during the
first 2 years after the onset of symptoms.
The Asymptomatic Carotid Atherosclerosis Study
showed a benefit of CEA in asymptomatic patients
with greater than 60% stenosis.24 Interestingly, the
numerical benefit was 5.9% for 5 years, a number
similar to that of symptomatic patients with 50% to
69% carotid stenosis (6.5%). Previous analysis results
have revealed that CEA in asymptomatic patients
with greater than 60% carotid stenosis is also cost-
effective but not to the same extent as for sympto-
matic patients with 50% to 69% stenosis.16,25 There
are interesting differences between these two cohorts
of patients. As previously noted, the benefit for
symptomatic patients with 50% to 69% stenosis was
greatest during the first 2 years after the inciting
event and only marginal thereafter. Consequently,
these patients do not need to survive for an extend-
ed period of time for CEA to be cost-effective. For
asymptomatic patients, the annual reduction in
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cient use of health care resources. CEA should be
considered for symptomatic patients with greater
than 50% carotid stenosis.
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Dr Robert W. Hobson II (Newark, NJ). Dr Patel and
her colleagues are to be congratulated for a scholarly pre-
sentation and a well-written manuscript on the cost-effec-
tiveness analyses for patients with symptomatic 50% to
69% stenoses of the extracranial carotid artery.
As emphasized by Dr Patel, recent NASCET publica-
tions have shown the efficacy of operation. However, they
did recommend caution because of the narrow margin of
benefit. Consequently, these observations with a Markov
process to analyze cost-effectiveness add a great deal to
DISCUSSION
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our anticipated use of operation in this subset of patients,
provided, as the authors emphasize, that the risk of 30-day
stroke and death can be held at less than 6.6%, that the age
of our patients is less than 83 years, and that the cost of
carotid endarterectomy can be maintained at or below
$15,000. This leads me to believe that we can be opti-
mistic about the use of endarterectomy in this subset of
symptomatic patients as parts of our program of stroke
prevention.
I have several questions for Dr Patel. I think it empha-
sizes the importance of not only looking at her data but also
analyzing and auditing our own experiences in our own
institutions. I think that is going to be very important.
My first concern has to do with the base-case cost of
$6400 for endarterectomy. And my question is whether
that is the cost for the 80% of patients who were opti-
mistically discharged on the first postoperative day or the
mean cost at your institution for all patients who under-
went carotid endarterectomy during the last year? We all
know of patients who have had complications and are in
the hospital for 2 to 5 days instead of the mean 1 or 2
days, and that could affect cost.
Also, have you conducted any cost assessments of adja-
cent institutions, wither academic or private, to see
whether the $6400 is a realistic figure? And, obviously,
that would be most important. I suspect that there may be
some of us in this audience for whom the cost of
endarterectomy for all patients who underwent treatment
during the last year may have approached the $15,000
range, which you have emphasized might invalidate the
operation.
The other important variable that was not evaluated
by these investigators was gender. The analysis by the
NASCET group showed a much lower benefit for opera-
tion in this subset of patients for women as compared with
men, and I wonder what the impact of gender analysis
might be on your modeling.
And finally, I wonder if there is anything you foresee
on the horizon medically in the way of new or antiplatelet
agents or other pharmaceuticals that might reduce the risk
of stroke in the medically treated group. As emphasized in
the manuscript, if we were to drop that figure during the
first year from 9% down to 4%, that might change the
equation substantially, and I wonder what your opinion is
about some of these newer agents.
I enjoyed reviewing this paper and think it is an impor-
tant contribution to our better understanding in the use of
carotid endarterectomy in this subset of patients. Thanks
very much.
Dr Sheela T. Patel. Thank you, Dr Hobson. For our
base case cost for carotid endarterectomy, we used a cost
of $6420, which was an average cost of the last 50 proce-
dures performed at New York Presbyterian Hospital. In
other publications, there have been other higher costs that
have not used cost-effective measures, such as selected
angiography and same-day admission. So, we realize that
there is wide variation in the cost, but this was the mean
cost for our hospital.
With respect to gender, we do not have all the vari-
ables to input for female patients who underwent carotid
endarterectomy with this degree of stenosis. So, although
the female patients did have a lower annual medical stroke
risk as compared with male patients, we do not have all the
variables to input. Thus, we do not know yet whether
women have less to benefit from carotid endarterectomy
and therefore whether it is less cost-effective in them.
With respect to antiplatelet agents, there have been
studies of various antiplatelet agents that may be more effec-
tive than the aspirin that was used in this therapy, but we do
not have sufficient data available to comment on that. This
trial only examined aspirin. So, once more data becomes
available, we will be able to input it into our model.
Dr Enrico Ascher (Brooklyn, NY). I very much
enjoyed this presentation, Dr Patel. I am trying to get
some practical applications from your data. Basically, if the
NASCET study did not show a statistically significant dif-
ference favoring surgery, then there is much we can do
about saying that it is cost-effective and maybe we should
do that. But once we have data published that says it is sta-
tistically significantly better to operate on these patients
with between 50% and 69% stenosis, what is the practical
application of that cost analysis? That is my first question.
Second, can someone use your data to suggest that
symptomatic patients who just turn 84 years of age should
not undergo operation? I do not think you are saying that,
but, again, I am trying to get some practical application.
I also believe, with the same enthusiasm, that we are
doing mathematical models and trying to diminish the
overall cost so that we can offer to more of our patients
this kind of procedure. I think we are missing the boat in
terms of screening these patients. I think there are a lot of
patients out there with 80% or 90% stenosis who are actu-
ally not being tested because we are not allowed to screen
patients. I think that, as vascular surgeons, we have the
moral obligation to impact on stroke. And describing all
the time that the number of stokes in this country is
700,000 or 800,000 a year is really not enough. We have
to do something about it. And as vascular surgeons, I
think it is our obligation to try to design a study where we
can screen those patients, detect the disease, and then per-
haps we would make an impact on the overall picture in
terms of diminishing the number of strokes and not see-
ing it going up every year.
I appreciate this paper and the opportunity to make
this speech. Thank you.
Dr Patel. Thank you. In terms of screening for patients
with 50% to 69% stenosis, we did not devise a model to
examine this question, but there have been other studies
that show that screening asymptomatic patients may be
cost-effective, but it might be marginal.
In terms of the practical applications of this model, we
are not saying that all patients aged 84 years or greater
with higher perioperative risks should not be operated.
This just provides a guideline for looking at a patient as a
whole, and you must individually make judgments on each
patient and decide from there.
